Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma

Bone Marrow Transplantation

Volumn 48, Issue 9, 2013, Pages 1212-1217

  Cohen, J B ^a   Hall, N C ^a   Ruppert, A S ^a   Jones, J A ^a   Porcu, P ^a   Baiocchi, R ^a   Christian, B A ^a   Penza, S ^a   Benson Jr, D M ^a   Flynn, J ^a   Andritsos, L A ^a   Devine, S M ^a   Blum, K A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Autologous transplantation; Mantle cell lymphoma; Non Hodgkin's lymphoma; PET and CT; SCT

Indexed keywords

BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB; VORINOSTAT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84883740312     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.46     Document Type: Article

References (21)

1. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009; 114: 1469-1476.
2. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
3. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
4. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101-6108.
5. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200-208.
6. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
7. Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving highdose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29: 3023-3029.
8. Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530-1533.
9. Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008; 49: 2081-2090.
10. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408-1418.
11. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012; 119: 1963-1971.
12. Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon L et al. Detection of minimal residual disease following inductionimmunochemotherapy predicts progression free survival inmantle cell lymphoma: final results of CALGB 59909. Haematologica 2011; 97: 579-585.
13. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53-59.
14. Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A et al. Positron emission tomography response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin lymphoma responding to prior salvage therapy. Haematologica 2012; 97: 1073-1079.
15. Dickinson M, Hoyt R, Roberts AW, Grigg A, Seymour JF, Prince HM et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pretransplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010; 150: 39-45.
16. Brepoels L, Stroobants S, De Wever W, Dierickx D, Vandenberghe P, Thomas J et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 1693-1701.
17. Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D et al. Posttreatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 2011; 118: 3565-3570.
18. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
19. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
20. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011; 29: 3194-3200.
21. Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010; 51: 2171-2180.